Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
17/11/202113:26Business WireAvoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate OfferNASDAQ:XLRNAcceleron Pharma Inc
09/11/202116:31Business WireAvoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate OfferNASDAQ:XLRNAcceleron Pharma Inc
04/11/202115:01Business WireAcceleron Reports Third Quarter 2021 Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
28/10/202107:00Business WireAvoro Capital Issues Open Letter to Fellow Acceleron Pharma ShareholdersNASDAQ:XLRNAcceleron Pharma Inc
27/10/202106:10Business WireAcceleron Announces Third Quarter 2021 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
30/09/202114:52Business WireAvoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron PharmaNASDAQ:XLRNAcceleron Pharma Inc
30/09/202106:34Dow Jones NewsMerck to Buy Acceleron Pharma for $11.5 BillionNASDAQ:XLRNAcceleron Pharma Inc
05/08/202115:01Business WireAcceleron Reports Second Quarter 2021 Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
28/07/202106:10Business WireAcceleron Announces Second Quarter 2021 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
26/07/202106:00Business WireAcceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021NASDAQ:XLRNAcceleron Pharma Inc
11/06/202102:00Business WireBristol Myers Squibb & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults ...NASDAQ:XLRNAcceleron Pharma Inc
08/06/202106:00Business WireAcceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021NASDAQ:XLRNAcceleron Pharma Inc
19/05/202107:00Business WireAcceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with ...NASDAQ:XLRNAcceleron Pharma Inc
19/05/202107:00Business WireAcceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at...NASDAQ:XLRNAcceleron Pharma Inc
12/05/202109:57Business WireAcceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congr...NASDAQ:XLRNAcceleron Pharma Inc
11/05/202106:00Business WireAcceleron to Host Conference Call & Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pul...NASDAQ:XLRNAcceleron Pharma Inc
06/05/202115:01Business WireAcceleron Reports First Quarter 2021 Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
29/04/202106:10Business WireAcceleron Announces First Quarter 2021 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
26/04/202106:00Business WireAcceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021NASDAQ:XLRNAcceleron Pharma Inc
05/04/202106:00Business WireAcceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH)...NASDAQ:XLRNAcceleron Pharma Inc
01/04/202106:00Business WireNew England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arter...NASDAQ:XLRNAcceleron Pharma Inc
25/02/202115:01Business WireAcceleron Reports Fourth Quarter and Full Year 2020 Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
23/02/202106:00Business WireAcceleron to Participate in Two Upcoming Healthcare Investor ConferencesNASDAQ:XLRNAcceleron Pharma Inc
17/02/202106:00Business WireAcceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021NASDAQ:XLRNAcceleron Pharma Inc
16/02/202106:37Business WireHealth Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndr...NASDAQ:XLRNAcceleron Pharma Inc
04/02/202106:10Business WireAcceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
04/01/202106:00Business WireAcceleron to Participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021NASDAQ:XLRNAcceleron Pharma Inc
14/12/202006:00Business WireAcceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (P...NASDAQ:XLRNAcceleron Pharma Inc
01/12/202006:00Business WireAcceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic SclerosisNASDAQ:XLRNAcceleron Pharma Inc
13/11/202009:01Business WireAcceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension ...NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN